摘要
目的探讨奥美拉唑联合低剂量吗替麦考酚酯在肾移植术后患者中的应用效果。方法选取2019年10月至2021年2月在郑州市第七人民医院经肾移植术治疗后的患者共58例,依据随机数字表法分为研究组(n=29)及对照组(n=29)。两组均采取奥美拉唑治疗,在此基础上对照组采取常规剂量吗替麦考酚酯,研究组采取低剂量吗替麦考酚酯。统计两组吗替麦考酚酯血药浓度、治疗前后肾功能指标[尿素氮(BUN)、血肌酐(Scr)、24 h尿蛋白定量(24hPRO)]、不良反应发生率、治疗有效率、术后急性排斥反应发生率以及生活质量。结果两组患者吗替麦考酚酯浓度、达峰时间相比,差异无统计学意义(P>0.05);研究组患者吗替麦考酚酯峰浓度低于对照组,差异有统计学意义(P<0.05)。治疗前,两组BUN、Scr、24hPRO水平对比差异无统计学意义(P>0.05),治疗后,两组患者BUN、Scr、24hPRO水平较治疗前降低,差异有统计学意义(P<0.05)。研究组不良反应发生率(6.90%)与对照组(20.69%)比较,差异无统计学意义(P>0.05)。研究组患者不良反应发生率及术后急性排斥反应发生率均低于对照组,两组患者治疗有效率对比,研究组高于对照组,但差异无统计学意义(P>0.05)。研究组生活质量评分高于对照组,差异有统计学意义(P<0.05)。结论奥美拉唑联合低剂量吗替麦考酚酯对治疗肾移植术后患者,肾功能恢复效果与常规剂量相当,且利于减少不良反应发生,具有安全性。
Objective To explore the application effect of omeprazole combined with low-dose mycophenolate mofetil in patients after kidney transplantation.Methods A total of 58 patients who underwent kidney transplant surgery at Zhengzhou Seventh People's Hospital from October 2019 to February 2021 were selected and divided into a study group(n=29)and a control group(n=29)based on a random number table method.Both groups were treated with omeprazole.On this basis,the control group received routine doses of mycophenolate mofetil,while the study group received low-dose mycophenolate mofetil.Calculate the blood concentration of mycophenolate mofetil in two groups,renal function indicators before and after treatment[blood urea nitrogen(BUN),serum creatinine(Scr),24-hour urine protein quantification(24-hour PRO)],incidence of adverse reactions,treatment effectiveness,incidence of postoperative acute rejection,and quality of life.Results There was no statistically significant difference in the concentration and peak time of mycophenolate mofetil between the two groups of patients(P>0.05);The peak concentration of mycophenolate mofetil in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of BUN,Scr,and 24-hour PRO between the two groups(P>0.05).After treatment,the levels of BUN,Scr,and 24-hour PRO in the two groups of patients decreased compared to before treatment,with a statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the study group(6.90%)and the control group(20.69%)(P>0.05).The incidence of adverse reactions and postoperative acute rejection in the study group were lower than those in the control group.The comparison of treatment effectiveness between the two groups showed that the study group was higher than the control group,but the difference was not statistically significant(P>0.05).The qu
作者
卢志贤
史佳佳
李冰玉
LU Zhixian;SHI Jiajia;LI Bingyu(Department of Nephrology and Renal Transplantation,Zhengzhou Seventh People's Hospital,Zhengzhou Henan 450000,China)
出处
《临床研究》
2023年第12期78-81,共4页
Clinical Research
关键词
吗替麦考酚酯
奥美拉唑
肾移植
肾功能
omeprazole
mortezolomide
renal transplantation
renal function
